Commentary · 27 May 2026
Conference abstractPublished 17 Sep 2018
What is and what is not type 2 diabetes
Universidade Federal Fluminense, Brazil
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Albeit diagnosed and defined as a â??primary sugar disease of the adult”; i.e., also as namely a disease of the carbohydrate metabolism by most authors; so-called type 2 diabetes mellitus should be better defined as a â??No Man’s Land” state of disease in adults, at most diagnosed by a fasting glycaemia equal or higher than 126 mg/dL and why this reality? Because in a global epidemic, which is badly out of control, among other reasons there is not much time to lose. So let’s get into some facts! Despite all controversies surrounding the etiology, pathogenesis and therapeutic roles for hyperglycemia in type 2 diabetes mellitus, new anti-hyperglycemic drugs are still getting into the market at a high speed, due to the overconfidence in HbA1c as a surrogate outcome for microvascular complications; albeit all large recent randomized clinical trials and meta-analysis have shown that trying to achieve glycemic levels close to the normal range did not reduce the most clinically important microvascular or macro-vascular hard endpoints as end-stage renal disease, vision loss, stroke, cardiovascular and total mortality, with the added harm of substantial increase in the number of hypoglycemic episodes and even death rates. If glucose or HbA1c were good surrogate disease markers, then why there is increased mortality in the ACCORD trial and the recent rosiglitazone saga, among other anti-hyperglycemic drugs? The above, among other core issues, will be covered during the presentation.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pancreatic Disorders & Therapy.
Short communication · 27 May 2026
Immunometabolic Interactions in Pancreatic Disease: Crosstalk Between Energy Dysregulation, Immune Activation, and Tissue Dysfunction
Commentary · 27 May 2026
Microvascular Dysfunction in Pancreatic Disorders: Endothelial Injury, Perfusion Failure, and Tissue Consequences
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPancreatic Disorders & Therapy
- SubjectGastroenterology & Hepatology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Jose Mario Franco de Oliveira”
